Recent studies conducted by Emory University are challenging the prevailing theories on the origin of Alzheimer’s disease, one of the leading causes of dementia worldwide.
The research, led by the team at the Goizueta Institute for Brain Health, introduces an innovative mechanism that could be responsible for the pathology.
Beta-amyloid and new proteins: an unexpected connection
In the article published in the journal Cell Reports Medicine, researchers Todd E.
Golde and Yona Levites explored the role of beta-amyloid deposits in the brains of patients with Alzheimer’s.
Traditionally, these accumulations have been identified as a hallmark of the disease, known for forming plaques that impair brain functions and cause cognitive decline.
However, the study proposes that other proteins accumulated around these plaques may be decisive in damaging brain cells. Using advanced analytical technologies, the researchers analyzed over 8,000 proteins in human brains affected by Alzheimer’s and in mouse models.
They identified more than 20 proteins that accumulate along with beta-amyloid in both human and mouse brains.
Among these proteins, midkine and pleiotrophin stood out for their ability to accelerate amyloid aggregation both in vitro and in animal models.
New therapeutic perspectives
This discovery opens new avenues for Alzheimer’s therapy, a notoriously difficult brain disease to treat despite decades of intensive research.
Although the fundamental principles of Alzheimer’s have been understood for over a century, the search for a cure has encountered numerous obstacles, with promising treatments often failing in experimental stages. The hypothesis advanced by the researchers at Emory University suggests that targeting these additional proteins could offer new therapeutic targets, not only for Alzheimer’s but also for other diseases related to amyloid accumulation in various tissues and organs of the human body.
Towards a new paradigm in Alzheimer’s research
This study represents a paradigm shift in the understanding of Alzheimer’s disease, proposing an alternative process of pathology development.
By targeting these additional proteins, it may be possible to develop innovative therapeutic approaches that go beyond traditional strategies focused solely on beta-amyloid. Ultimately, the research conducted by Emory University could revolutionize not only the fight against Alzheimer’s but also the general approach to diseases related to the accumulation of abnormal proteins, offering new hopes for the treatment of these complex pathologies.
Follow our feed
